Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis
Authors:
- 17 December 2022
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23 (3) , e139-e149
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Childhood Acute Lymphoblastic Leukemia: Progress Through CollaborationJournal of Clinical Oncology, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2014
- Survival improvement by decade of patients aged 0–14 years with acute lymphoblastic leukemia: a SEER analysisScientific Reports, 2014
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBritish Journal of Haematology, 2012
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExperimental Cell Research, 2011
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryBlood, 2009
- The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructCancer Immunology, Immunotherapy, 2007